Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $25.98 USD
Change Today -0.67 / -2.51%
Volume 56.8K
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

paratek pharmaceuticals inc (PRTK) Snapshot

Open
$26.33
Previous Close
$26.65
Day High
$26.99
Day Low
$25.15
52 Week High
12/31/14 - $39.80
52 Week Low
10/24/14 - $11.30
Market Cap
456.2M
Average Volume 10 Days
69.5K
EPS TTM
$-7.29
Shares Outstanding
17.6M
EX-Date
10/31/14
P/E TM
--
Dividend
--
Dividend Yield
30.83%
Current Stock Chart for PARATEK PHARMACEUTICALS INC (PRTK)

paratek pharmaceuticals inc (PRTK) Related Bloomberg News

View More Bloomberg News

paratek pharmaceuticals inc (PRTK) Related Businessweek News

No Related Businessweek News Found

paratek pharmaceuticals inc (PRTK) Details

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

29 Employees
Last Reported Date: 08/11/15

paratek pharmaceuticals inc (PRTK) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $128.5K
President, Chief Medical Officer and Director
Total Annual Compensation: $488.8K
Chief Financial Officer and Secretary
Total Annual Compensation: $10.4K
Vice President of Research and Development
Total Annual Compensation: $226.0K
Compensation as of Fiscal Year 2014.

paratek pharmaceuticals inc (PRTK) Key Developments

Paratek Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Paratek Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $15,679,000 against $1,881,000 a year ago. Net loss attributable to common stockholders was $15,699,000 or $0.96 per basic and diluted share against $3,007,000 or $41.79 per basic and diluted share a year ago. For the six months, the company reported loss from operations of $26,312,000 against $2,812,000 a year ago. Net loss attributable to common stockholders was $26,332,000 or $1.71 per basic and diluted share against $4,420,000 or $63.32 per basic and diluted share a year ago.

Paratek Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 05, 2015

Paratek Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 9:36 PM, GMT Standard Time on Aug 05, 2015

Paratek Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 05, 2015

Paratek Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTK:US $25.98 USD -0.67

PRTK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTK.
View Industry Companies
 

Industry Analysis

PRTK

Industry Average

Valuation PRTK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 109.1x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 79.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PARATEK PHARMACEUTICALS INC, please visit www.paratekpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.